Genetic disease company Vertex Pharmaceuticals (Nasdaq: VRTX) has secured conditional marketing authorization for Casgevy (exagamglogene autotemcel) in Europe.
Also known as exa-cel, the product is a CRISPR/Cas9 gene-edited therapy for people with severe sickle cell disease (SCD).
Contingent on further data confirming benefit, the European Commission has authorized marketing of the product for certain patients over the age of 12, where a matched stem
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user pleaselogin. If your trial has come to an end, you cansubscribe here.
Try before you buy
All the news that moves the needle in pharma and biotech. Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters. Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
Unfettered access to industry-leading news, commentary and analysis in pharma and biotech. Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results. Daily roundup of key events in pharma and biotech. Monthly in-depth briefings on Boardroom appointments and M&A news. Choose from a cost-effective annual package or a flexible monthly subscription.
Read more from the original source:
Revolution in sickle cell disease treatment on the way in Europe - The Pharma Letter
Recommendation and review posted by G. Smith
